SCYNEXIS Company Profile (NASDAQ:SCYX)

About SCYNEXIS (NASDAQ:SCYX)

SCYNEXIS logoSCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SCYX
  • CUSIP: N/A
  • Web: www.scynexis.com
Capitalization:
  • Market Cap: $41.02 million
  • Outstanding Shares: 25,798,000
Average Prices:
  • 50 Day Moving Avg: $2.35
  • 200 Day Moving Avg: $3.04
  • 52 Week Range: $1.55 - $5.51
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.14
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $256,999.00
  • Price / Sales: 159.61
  • Book Value: $1.31 per share
  • Price / Book: 1.21
Profitability:
  • EBIDTA: ($26,600,000.00)
  • Net Margins: -13,335.88%
  • Return on Equity: -83.00%
  • Return on Assets: -62.52%
Debt:
  • Debt-to-Equity Ratio: 0.43%
  • Current Ratio: 13.45%
  • Quick Ratio: 13.45%
Misc:
  • Average Volume: 471,168 shs.
  • Beta: 0.3
  • Short Ratio: 7.57
 

Frequently Asked Questions for SCYNEXIS (NASDAQ:SCYX)

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

How were SCYNEXIS's earnings last quarter?

SCYNEXIS Inc (NASDAQ:SCYX) released its quarterly earnings data on Monday, August, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by $0.04. The company had revenue of $0.06 million for the quarter. SCYNEXIS had a negative net margin of 13,335.88% and a negative return on equity of 83.00%. View SCYNEXIS's Earnings History.

Where is SCYNEXIS's stock going? Where will SCYNEXIS's stock price be in 2017?

8 analysts have issued 1 year price objectives for SCYNEXIS's stock. Their forecasts range from $7.00 to $16.00. On average, they expect SCYNEXIS's share price to reach $11.57 in the next twelve months. View Analyst Ratings for SCYNEXIS.

What are analysts saying about SCYNEXIS stock?

Here are some recent quotes from research analysts about SCYNEXIS stock:

  • 1. According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (3/17/2017)
  • 2. Guggenheim analysts commented, "Post 4Q16, we remain positive on SCYX because we believe SCY-078 still has a viable future and is differentiated as a potential IV-oral stepdown therapy for invasive fungal infections, an area of unmet need that is difficult to treat. While the delay in the IV formulation is not ideal, SCYX was not going to move forward with the high doses where the thrombotic events were experienced. SCYX will meet the FDA in 2Q17 to discuss a path forward for the IV formulation. Importantly, oral SCY-078 development is not affected, and SCYX continues to move forward with the rest of its pipeline assets as well." (3/14/2017)
  • 3. Needham & Company LLC analysts commented, "Scynexis announced late yesterday that FDA has placed a clinical hold on IV SCY-078. Oral program is not affected. Mgmt disclosed yesterday there were three mild-moderate catheter-site thrombotic events in the previously completed IV SCY-078 Phase 1 trial in healthy volunteers. These events were associated with the highest doses and highest concentrations tested in the trial. Mgmt stated these doses are higher than needed for efficacy based on preclinical and clinical PK/PD data and the company had proposed a lower dose for Phase 2 and 3 development. Mgmt plans to meet with FDA in 2Q17 to review safety profile and rationale for dose selection. Based on available information, our bias is that this issue can be resolved w/o changes or w/ administration of lower concentration of drug and/or longer administration time. It is possible clinical hold may result in only one quarter delay (Phase 2 initiation had been expected 1Q17). However, we note there is a risk the FDA may determine IV SCY-078 therapeutic window is not wide enough, resulting in delays (develop alternative formulations; additional PK/PD work; changes to administration regimen) or an end to IV program. We believe the latter is unlikely." (3/3/2017)
  • 4. HC Wainwright analysts commented, "Treatment landscape improved, but inflammation persists: We initiated our discussion covering the positive impact of CFTR modulating therapies Kalydeco and Orkambi, which have established significant improvements in a small set of CF patients and more modest improvement across the broader CF population, respectively. Corbus’ Phase 2 CF study allows for patients on stable regimens of Orkambi or Kalydeco, whose benefit has been reached by the time they enter the Corbus trial." (2/22/2017)
  • 5. Aegis analysts commented, "We are initiating coverage of Scynexis with a Buy rating and a price target of $7 per share. Scynexis is a clinical stage biotechnology company developing a new class of anti-fungal drugs. The lead molecule, SCY-078, has the same target as the current echinocandin class but can be formulated for both oral or intravenous administration. It is a structurally different molecule with different pharmacological properties and not simply an oral version of an existing drug. Clinical testing has shown SCY-078 has a broader spectrum of activity than the current echinocandins, including efficacy against the mutated fungal strains that resist treatment and are making the current drugs ineffective." (1/31/2017)

Who are some of SCYNEXIS's key competitors?

Who owns SCYNEXIS stock?

SCYNEXIS's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (5.79%), FMR LLC (5.22%), Vanguard Group Inc. (3.21%), Iguana Healthcare Management LLC (1.18%), Principal Financial Group Inc. (0.79%) and Private Advisor Group LLC (0.79%). Company insiders that own SCYNEXIS stock include Ann Hanham, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti and Patrick Machado. View Institutional Ownership Trends for SCYNEXIS.

Who sold SCYNEXIS stock? Who is selling SCYNEXIS stock?

SCYNEXIS's stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P.. View Insider Buying and Selling for SCYNEXIS.

Who bought SCYNEXIS stock? Who is buying SCYNEXIS stock?

SCYNEXIS's stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Private Advisor Group LLC, KCG Holdings Inc., Dynamic Technology Lab Private Ltd, Iguana Healthcare Management LLC, Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought SCYNEXIS stock in the last two years include Ann Hanham, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti and Patrick Machado. View Insider Buying and Selling for SCYNEXIS.

How do I buy SCYNEXIS stock?

Shares of SCYNEXIS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of SCYNEXIS stock cost?

One share of SCYNEXIS stock can currently be purchased for approximately $1.59.

Analyst Ratings

Consensus Ratings for SCYNEXIS (NASDAQ:SCYX) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.57 (627.76% upside)

Analysts' Ratings History for SCYNEXIS (NASDAQ:SCYX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/9/2017Needham & Company LLCDowngradeBuy -> HoldHighView Rating Details
4/15/2017HC WainwrightSet Price TargetBuy$14.00LowView Rating Details
3/14/2017GuggenheimReiterated RatingBuy$15.00HighView Rating Details
3/3/2017Royal Bank of CanadaReiterated RatingOutperform$15.00 -> $11.00N/AView Rating Details
1/31/2017AegisInitiated CoverageBuy$7.00N/AView Rating Details
10/7/2016WBB SecuritiesUpgradeBuy -> Strong-Buy$8.00N/AView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
6/9/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for SCYNEXIS (NASDAQ:SCYX)
Earnings by Quarter for SCYNEXIS (NASDAQ:SCYX)
Earnings History by Quarter for SCYNEXIS (NASDAQ:SCYX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q216($0.52)($0.56)$0.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.63)($0.52)$0.06 millionViewN/AView Earnings Details
11/13/2015Q315($0.62)($0.60)$0.06 millionViewN/AView Earnings Details
5/15/2015Q115($0.43)($0.75)$4.20 million$2.31 millionViewN/AView Earnings Details
3/30/2015($0.71)($0.45)$5.30 millionViewN/AView Earnings Details
11/13/2014($0.53)($0.45)$4.38 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for SCYNEXIS (NASDAQ:SCYX)
Current Year EPS Consensus Estimate: $-1.24 EPS
Next Year EPS Consensus Estimate: $-1.39 EPS

Dividends

Dividend History for SCYNEXIS (NASDAQ:SCYX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for SCYNEXIS (NASDAQ:SCYX)
Insider Ownership Percentage: 3.91%
Institutional Ownership Percentage: 47.81%
Insider Trades by Quarter for SCYNEXIS (NASDAQ:SCYX)
Institutional Ownership by Quarter for SCYNEXIS (NASDAQ:SCYX)
Insider Trades by Quarter for SCYNEXIS (NASDAQ:SCYX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Gonzalez David AnguloInsiderBuy15,000$1.70$25,500.00View SEC Filing  
5/12/2017Marco TagliettiCEOBuy25,000$1.69$42,250.00View SEC Filing  
12/21/2016Marco TagliettiCEOBuy25,000$3.30$82,500.00View SEC Filing  
12/16/2016Gonzalez David AnguloInsiderBuy4,000$3.25$13,000.00View SEC Filing  
9/15/2016Patrick MachadoDirectorBuy40,000$2.94$117,600.00View SEC Filing  
6/30/2016Gonzalez David AnguloInsiderBuy36,950$2.22$82,029.00View SEC Filing  
6/24/2016Eric FrancoisCFOBuy15,000$2.39$35,850.00View SEC Filing  
6/24/2016Guy MacdonaldDirectorBuy40,000$2.39$95,600.00View SEC Filing  
6/24/2016Marco TagliettiCEOBuy100,000$2.39$239,000.00View SEC Filing  
5/25/2016Ann HanhamDirectorBuy4,225$3.64$15,379.00View SEC Filing  
5/25/2016Marco TagliettiCEOBuy5,754$3.26$18,758.04View SEC Filing  
5/24/2016Marco TagliettiCEOBuy5,500$3.37$18,535.00View SEC Filing  
5/23/2016Marco TagliettiCEOBuy7,500$3.14$23,550.00View SEC Filing  
5/19/2016Marco TagliettiCEOBuy6,000$3.07$18,420.00View SEC Filing  
11/24/2015Marco TagliettiCEOBuy22,733$6.79$154,357.07View SEC Filing  
8/31/2015Marco TagliettiCEOBuy25,000$7.82$195,500.00View SEC Filing  
8/28/2015Marco TagliettiCEOBuy2,267$7.08$16,050.36View SEC Filing  
8/26/2015Marco TagliettiCEOBuy50,000$7.07$353,500.00View SEC Filing  
5/7/2014Jean-Yves NothiasDirectorBuy50,000$10.00$500,000.00View SEC Filing  
5/7/2014Ventech Capital IiMajor ShareholderBuy28,000$10.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for SCYNEXIS (NASDAQ:SCYX)
Latest Headlines for SCYNEXIS (NASDAQ:SCYX)
Source:
DateHeadline
seekingalpha.com logoScynexis: Another Buy Opportunity On The Recent Pullback - Seeking Alpha
seekingalpha.com - May 17 at 7:17 AM
finance.yahoo.com logoETFs with exposure to SCYNEXIS, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 6:57 PM
americanbankingnews.com logoGonzalez David Angulo Acquires 15,000 Shares of SCYNEXIS Inc (SCYX) Stock
www.americanbankingnews.com - May 15 at 11:52 AM
americanbankingnews.com logoMarco Taglietti Purchases 25,000 Shares of SCYNEXIS Inc (SCYX) Stock
www.americanbankingnews.com - May 15 at 11:42 AM
finance.yahoo.com logoSCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 11:24 PM
finance.yahoo.com logoPotent in vitro Activity of SCYNEXIS’ SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention (CDC)
finance.yahoo.com - May 11 at 8:12 PM
seekingalpha.com logoScynexis: Time To Abandon Ship? - Seeking Alpha
seekingalpha.com - May 11 at 1:00 AM
finance.yahoo.com logoSHAREHOLDER ANNOUNCEMENT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017
finance.yahoo.com - May 8 at 7:13 PM
finance.yahoo.com logoSCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status
finance.yahoo.com - May 8 at 7:13 PM
marketbeat.com logoScynexis reports 1Q loss
marketbeat.com - May 8 at 4:53 PM
americanbankingnews.com logoSCYNEXIS Inc (SCYX) Expected to Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - May 8 at 12:22 PM
finance.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against SCYNEXIS, Inc. (SCYX) & Lead Plaintiff Deadline - May 8, 2017
finance.yahoo.com - May 8 at 11:32 AM
finance.yahoo.com logoDEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017 - SCYX
finance.yahoo.com - May 8 at 11:32 AM
finance.yahoo.com logoDEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 8 at 11:32 AM
finance.yahoo.com logoMAY 8 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 6 at 1:04 AM
americanbankingnews.com logoSCYNEXIS Inc (SCYX) Receives $10.56 Average PT from Brokerages
www.americanbankingnews.com - May 5 at 11:44 PM
finance.yahoo.com logoDEADLINE MONDAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving SCYNEXIS, Inc. and a Lead Plaintiff Deadline of May 8, 2017
finance.yahoo.com - May 5 at 8:03 PM
finance.yahoo.com logoMONDAY DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 4 at 8:01 PM
finance.yahoo.com logoDEADLINE ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 7:11 PM
finance.yahoo.com logo5-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 7:11 PM
americanbankingnews.com logoSCYNEXIS (SCYX) Receives Media Impact Score of 0.16
www.americanbankingnews.com - May 3 at 1:02 AM
americanbankingnews.com logoSCYNEXIS Inc (SCYX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 6:54 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a ... - Yahoo Finance
finance.yahoo.com - May 2 at 5:34 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017 - SCYX
finance.yahoo.com - May 1 at 6:57 PM
finance.yahoo.com logo7-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 1 at 6:57 PM
finance.yahoo.com logoUPCOMING DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 29 at 2:00 AM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against SCYNEXIS, Inc. - SCYX
finance.yahoo.com - April 28 at 8:59 PM
americanbankingnews.com logoSCYNEXIS (SCYX) Earning Somewhat Favorable News Coverage, Study Finds
www.americanbankingnews.com - April 28 at 6:50 PM
finance.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against SCYNEXIS, Inc. (SCYX) and Lead Plaintiff Deadline - May 8, 2017
finance.yahoo.com - April 28 at 3:58 PM
finance.yahoo.com logoDEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and …
finance.yahoo.com - April 27 at 8:09 PM
finance.yahoo.com logoDEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 27 at 8:09 PM
streetinsider.com logoScynexis (SCYX) Says Eight Data Presentations at ECCMID Showcase Broad Applicability of SCY-078 - StreetInsider.com
www.streetinsider.com - April 26 at 9:14 PM
seekingalpha.com logoSCYNEXIS (SCYX) ECCMID SCY-078 Scientific Data Presentation Conference Call - Slideshow
seekingalpha.com - April 26 at 4:13 PM
finance.yahoo.com logoAPPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. …
finance.yahoo.com - April 26 at 9:25 AM
finance.yahoo.com logoAPPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 26 at 9:25 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 25 at 6:48 PM
finance.yahoo.com logoAPPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 25 at 6:48 PM
finance.yahoo.com logoSCYX EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving SCYNEXIS, Inc. and a Lead Plaintiff Deadline of May 8, 2017
finance.yahoo.com - April 25 at 6:48 PM
americanbankingnews.com logoSCYNEXIS (SCYX) Receiving Somewhat Negative Press Coverage, Report Finds
www.americanbankingnews.com - April 25 at 6:41 PM
finance.yahoo.com logoEight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS’ Lead Anti-infective Candidate SCY-078
finance.yahoo.com - April 25 at 9:58 AM
finance.yahoo.com logoEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017 - SCYX
finance.yahoo.com - April 24 at 6:10 PM
finance.yahoo.com logoSHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in SCYNEXIS, Inc. of Class Action Lawsuit and Upcoming Deadline – SCYX
finance.yahoo.com - April 24 at 11:38 AM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 24 at 11:38 AM
americanbankingnews.com logoSCYNEXIS (SCYX) Getting Somewhat Negative Press Coverage, Report Shows
www.americanbankingnews.com - April 21 at 9:22 PM
finance.yahoo.com logoSCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID
finance.yahoo.com - April 21 at 7:32 PM
prnewswire.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100000 ... - PR Newswire (press release)
www.prnewswire.com - April 21 at 8:14 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of Commencement of a Class ... - Yahoo Finance
finance.yahoo.com - April 21 at 8:14 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against SCYNEXIS, Inc. (SCYX) and Lead Plaintiff Deadline - May 8, 2017
finance.yahoo.com - April 20 at 7:48 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017 - SCYX
finance.yahoo.com - April 20 at 7:48 PM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 20 at 7:48 PM

Social

SCYNEXIS (SCYX) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff